A tour de force provides novel insights into CD19-CAR T cell resistance mechanisms

Aimee C Talleur; Stephen Gottschalk

doi:10.1016/j.xcrm.2023.100949

A tour de force provides novel insights into CD19-CAR T cell resistance mechanisms

Cell Rep Med. 2023 Feb 21;4(2):100949. doi: 10.1016/j.xcrm.2023.100949.

Authors

Aimee C Talleur¹, Stephen Gottschalk²

Affiliations

¹ Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, USA.
² Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, USA. Electronic address: [email protected].

Abstract

Sworder et al.¹ developed an integrated simultaneous tumor and effector profiling (STEP) approach to study resistance mechanisms to CD19-CAR T cell therapy in large B-cell lymphomas. Their study provides novel biological insights and paves the way for future interventions.

MeSH terms

Biochemical Phenomena*
Immunotherapy, Adoptive
Receptors, Antigen, T-Cell*
T-Lymphocytes

Substances

Receptors, Antigen, T-Cell